Premier Biomedical Announces Payoff of Liabilities; Funding for Research and Development

SOURCE: Premier Biomedical, Inc.

EL PASO, TX--(Marketwired - Mar 12, 2014) - Premier Biomedical, Inc. (OTCQB: BIEI) a biopharmaceutical company focused on developing and commercializing innovative immune-system manipulation therapies for breast cancer, as well as potential novel therapies for Alzheimer's disease, multiple sclerosis (MS), and traumatic brain injury, announced today that through its equity funding arrangement with Kodiak Capital Group, LLC, which was announced in December 2013, it has paid all its liabilities and anticipates having sufficient capital to fund current on-going and mid-term research and development.

"We are extremely pleased to move forward with our research and development program as we recently received extremely positive results from duplicate studies on our newest Breast Cancer treatment, which will be formally presented to the American Association for Cancer Research (AACR) annual meeting in San Diego in April.While funding innovative research is a challenge regardless of the industry, our progress toward our goals has been recognized by a global capital investment firm," said Premier Biomedical, Inc. CEO William A. Hartman. "We are in a strong position to focus on the future along with our partners in R&D, the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso, and the acceleration of our research to bring successful treatments to market for many of today's most dreadful diseases."

About Premier Biomedical, Inc. Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, in collaboration with the University of Texas at El Paso and US Department of Defense, specifically targeting the treatment of Alzheimer's disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in El Paso, Texas, with business offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/

About Kodiak Capital Group, LLC Kodiak is an institutional investor headquartered in Newport Beach, CA. Kodiak makes private investments in public and private entities utilizing proprietary equity and debt instruments.These investments provide long-term strategic capital offering companies certainty, flexibility and consistency. Kodiak's investments are in a wide range of industries emphasizing alternative energy, consumer products, life sciences, natural resources, and social media technology. For more information, visit http://www.kodiak-capital.us.

Safe Harbor Notice Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

See the article here:
Premier Biomedical Announces Payoff of Liabilities; Funding for Research and Development